StrataGraft Safety, Tolerability and Efficacy in Pediatric Subjects

Inclusion Criteria: * Written informed consent provided by the parent(s) or legal guardian(s) and assent from the child when appropriate * Have enough healthy skin to reserve as donor site(s), in case autografting becomes necessary * Thermal burns of no more than a total of 30% TBSA * Study treatment sites that are DPT in depth and which are clinically indicated for excision and autografting, and located on the torso or extremities * Study treatment area(s) totaling 0.5% to 10% TBSA and may be composed of up to 3 non-contiguous areas located on the same extremity or plane of the torso * Sufficient healthy skin available and reserved as a donor site in the event that the StrataGraft treatment site requires autografting Exclusion Criteria: * Is pregnant or breastfeeding * Receiving treatment to suppress the immune system and/or systemic corticosteroids (inhaled corticosteroids are permitted) * A known history of malignancy * Pre-admission insulin-dependent diabetes * Concurrent trauma, conditions, and/or personal situations that, in the opinion of the investigator, may compromise the participant's safety or the study objectives * A burn injury that occurred ≥ 14 days prior to planned StrataGraft application Is expected to survive less than 12 months * Is participating in another interventional trial, or did within 90 days before enrollment * A proposed study treatment site that has been previously excised or autografted; located adjacent to an undebrided/unexcised burn area; demonstrates signs and symptoms of wound infection, per judgement of the clinical investigator; lies across joints or is located on the feet (i.e., distal to the malleolus), hands (distal to the wrist), face, neck, buttocks, perineum, or genitalia